# Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs

> **NCT04852679** · PHASE3 · COMPLETED · sponsor: **Ipsen** · enrollment: 43 (actual)

## Conditions studied

- Gastroenteropancreatic Neuroendocrine Tumor

## Interventions

- **DRUG:** Lanreotide autogel

## Key facts

- **NCT ID:** NCT04852679
- **Lead sponsor:** Ipsen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-24
- **Primary completion:** 2022-06-10
- **Final completion:** 2023-01-13
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2024-10-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04852679

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04852679, "Study to Assess the Efficacy and Safety of Lanreotide Autogel® in Chinese Participants With GEP-NETs". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04852679. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*